1H 2024: Final results of Phase 1 azenosertib + chemotherapy trial in osteosarcoma. 2H 2024: Final results of Phase 1b azenosertib monotherapy trial in solid tumors; Topline data from Phase 1/2 azenosertib + PARP inhibitor and azenosertib monotherapy trial in platinum resistant ovarian cancer in partnership with GSK; Initial data from Phase 1 azenosertib + BEACON regimen trial in BRAF mutant metastatic colorectal cancer in partnership with Pfizer; Initial data from Phase 1 of azenosertib + ZN-d5 trial in R/R AML; Additional details on planned clinical trial of azenosertib in PSOC in the 1L maintenance setting. 1H 2025: Topline data from Phase 2 azenosertib monotherapy trial in platinum resistant high-grade serous ovarian cancer. 2H 2025: Topline data from Phase 2 azenosertib monotherapy trial in recurrent or persistent USC. 2025: Initiate clinical trial of azenosertib in PSOC in the 1L maintenance setting. 2026: First NDA for azenosertib in a gynecologic malignancy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ZNTL:
- Zentalis Pharmaceuticals Updates Bylaws for Enhanced Governance
- Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Immunome initiated with an Outperform at Leerink
- Zentalis Pharmaceuticals Issues Regulation FD Disclosure Statement
